NEW YORK ( TheStreet) -- Transcept Pharmaceuticals (Nasdaq: TSPT) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 167.0% when compared to the same quarter one year ago, falling from -$1.94 million to -$5.18 million.
- The share price of TRANSCEPT PHARMACEUTICALS has not done very well: it is down 20.94% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The gross profit margin for TRANSCEPT PHARMACEUTICALS is currently extremely low, coming in at 0.00%. Despite the low profit margin, it has increased significantly from the same period last year.
- TRANSCEPT PHARMACEUTICALS has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, TRANSCEPT PHARMACEUTICALS continued to lose money by earning -$0.31 versus -$0.70 in the prior year. For the next year, the market is expecting a contraction of 377.4% in earnings (-$1.48 versus -$0.31).
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, TRANSCEPT PHARMACEUTICALS's return on equity significantly trails that of both the industry average and the S&P 500.
-- Written by a member of TheStreet Ratings Staff